DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Otros (Other)
Synergistic antiviral effects of structure-guided peptides and a mutagenic base analog on SARS-CoV-2 replication
The limited durability of vaccine protection and the rapid emergence of SARS-CoV-2 variants highlight the need for antiviral strategies that extend beyond vaccination and conventional small-molecule inhibitors. Here, we explored a dual approach combining structure-guided peptides predicted to interfere with the viral replication complex with lethal mutagenesis to limit SARS-CoV-2 replication. Using the crystallographic interfaces of nsp10 with nsp14 and nsp16, we designed short inhibitory peptides predicted to interact with the viral proofreading and RNA-capping machinery. In parallel, the mutagenic analog 5-fluorouracil was evaluated to determine its effect on SARS-CoV-2 in Vero E6 cells. Peptides P1 and P6 exhibited potent antiviral activity with minimal cytotoxicity, whereas 5-FU reduced specific infectivity without impairing genome replication. Combined treatment with 5-FU and peptide P1 resulted in >104-fold reduction in infectious virus, achieving near-complete loss of infectivity at non-cytotoxic concentrations. Next-generation sequencing revealed that dual treatment increased mutation frequency, altered mutant spectra, and decreased genome stability, consistent with progression toward error catastrophe. Principal component analysis confirmed that combined treatment generated mutant spectra distinct from either monotherapy. These findings are consistent with a dual antiviral strategy in which structure-guided peptides designed to interact with components of the SARS-CoV-2 replication complex act in combination with lethal mutagenesis to produce a synergistic interaction between these two complementary processes. This integrated approach suggests a potential broad-spectrum antiviral strategy with applicability to other coronaviruses., This work was funded by grant CV20-10932 (PI: AG-P) from the Junta de Andalucía, co-financed with FEDER funds, and partially funded by Fundación Bancaria Unicaja. Partial funding for open access charges was provided by the Universidad de Málaga. U.B. was supported by grant PID2023-151032NB-C2 from the Spanish Ministry of Science (MCIU), the Spanish Research Agency (AEI/10.13039/501100011033/), and FEDER, EU. Research at the CBMSO is facilitated by the Fundación Ramón Areces and supported by the Ministerio de Ciencia, Innovación y Universidades (MICIU), through grant PID2023-146622OB-I00, financed by MICIU/AEI/10.13039/501100011033 and FEDER, EU, and by the “Severo Ochoa” Program for Centres of Excellence in Research and Development (CEX2021- 001154-S). We also acknowledge project TEC-607 2024/BIO-66 (SALAINDEC-CM from Comunidad de Madrid/FEDER).
S.O.D.C. acknowledges financial support from Fundación Martín Varona. A.M.F.E. acknowledges a Teaching Staff Retraining Grant (2023), Spanish Ministry of Universities, and CIBEST/2024/114 from Generalitat Valenciana. We thank Dr. Luis Enjuanes (CNB-CSIC, Spain) for providing Vero E6 cells and Dr. Francisco Sobrino (CBMSO) for providing the VFA control peptide, Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2023-151032NB-C21
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2023-151032NB-C22
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2023-146622OB-I00